Q3 Earnings Forecast for Omnicell Issued By Zacks Research

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research reduced their Q3 2026 earnings per share (EPS) estimates for shares of Omnicell in a note issued to investors on Thursday, February 26th. Zacks Research analyst Team now expects that the company will post earnings of $0.25 per share for the quarter, down from their previous forecast of $0.29. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.28 EPS.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The company had revenue of $313.98 million during the quarter, compared to analysts’ expectations of $313.36 million. During the same quarter in the previous year, the business posted $0.60 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

A number of other equities research analysts have also weighed in on OMCL. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective on the stock in a report on Wednesday, February 4th. Weiss Ratings upgraded Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, February 9th. Benchmark upped their price objective on Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Wells Fargo & Company increased their price objective on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, Wall Street Zen cut Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Omnicell Stock Down 2.0%

Shares of Omnicell stock opened at $41.10 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.00. The company has a market capitalization of $1.84 billion, a P/E ratio of 1,027.76, a P/E/G ratio of 1.44 and a beta of 0.78. The company has a 50 day moving average of $45.05 and a 200 day moving average of $37.96.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. acquired a new stake in shares of Omnicell in the second quarter valued at approximately $26,000. First Horizon Corp purchased a new stake in Omnicell in the 3rd quarter valued at $31,000. Farther Finance Advisors LLC boosted its stake in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after purchasing an additional 1,036 shares during the period. Clearstead Advisors LLC grew its position in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in Omnicell in the fourth quarter valued at $58,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.52% of the company’s stock.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: The bull case: several recent pieces lay out a bullish thesis that Omnicell’s medication‑management automation, recurring revenue mix and potential margin recovery create upside if execution improves and multiples re‑rate. These write‑ups are drawing investor interest in a longer‑term recovery story. Omnicell, Inc. (OMCL): A Bull Case Theory
• Neutral Sentiment: Analyst consensus snapshot: aggregate broker sentiment remains mixed — one recent summary noted an average “Moderate Buy” analyst rating, which offsets some of the negative headlines but doesn’t eliminate near‑term execution risk. Omnicell Receives Average Rating of “Moderate Buy”
• Negative Sentiment: Zacks Research adjustments: Zacks issued a string of estimate downgrades for FY2026 and several 2026 quarters while keeping a “Strong Sell” rating — they lowered FY2026 EPS and near‑term quarterly targets (Q3/Q4 2026) even as they trimmed/raised some out‑year estimates. The combination of reduced near‑term earnings and a negative analyst stance is likely weighing on the stock today.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.